Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

About this update from Henry Schein, Inc.

Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value AMERICAN FORK, Utah--(BUSINESS WIRE)-- Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year’s data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution. Across both DSOs and independent practices, the highest-performing organizations consistently outperform their peers not because they are larger, but because they deliver more complete, consistent care. It is clear that growth-focused practices invest in building patient trust at the chairside. That difference shows directly in financial outcomes. According to the 2026 Catalyst Index, top performers achieve 75% case acceptance compared to 45% for the average practice, alongside stronger production, collections, and patient engagement, reinforcing that performance begins at the point of care and carries through the entire business. “Across the data, the pattern is consistent. Growth follows clinical performance,” said Dr. Ryan Hungate, Chief Clinical and Strategy Officer, Henry Schein One. “When clinicians are supported to deliver complete care and clear communication, patients move forward with treatment. That’s what drives predictable revenue. It starts chairside and flows through the entire system.” The report challenges one of the industry’s most persistent assumptions: that scale alone creates better outcomes. Performance varies widely within every segment. Smaller practices often match or outperform larger groups, while many DSOs face increasing complexity without corresponding gains in efficiency or profitability. For operators and investors, the implication is clear: growth strategies built on scale alone increase complexity, while scaling consistent clinical execution drives predictable performance and long-term value creation. “The idea that scale automatically creates better performance doesn’t always hold up,” said Brian Colao, Director of the DSO Industry Group, Dykema. “What separate...

View stock analysis, news, and events for Henry Schein, Inc.